A Randomized, Double-blind, Placebo-controlled Phase IIB Study Evaluating the Efficacy of Mesdopetam on Daily ON-time Without Troublesome Dyskinesia in Patients With Parkinson's Disease

This is a Phase 2b study investigating the efficacy and safety of mesdopetam as adjunct therapy on daily ON-time without troublesome dyskinesia in patients with Parkinson disease. Mesdopetam is taken for 84 days.

开始日期2020-10-29

申办/合作机构

IRLAB Therapeutics AB

NCT03368170

/ Completed临床2期

A Randomized, Placebo-controlled, Phase IIa Study Evaluating the Efficacy and Tolerability of IRL790 in Parkinson's Disease Dyskinesia

Mesdopetam (IRL790) is an experimental small molecule compound with psychomotor stabilizing properties. The primary target is the dopamine D3 receptor, a target implicated in the generation of levodopa-induced dyskinesia, a side-effect frequently occurring with long-term levodopa treatment in patients with Parkinson's disease. In experimental animals mesdopetam potently reduced levodopa-induced involuntary movement without impairing the antiparkinsonian effect of levodopa.
The primary purpose of the trial is to investigate whether mesdopetam given as adjunctive treatment can reduce levodopa induced dyskinesia in patients with Parkinson's disease. The trial will also help to establish the most optimal dosing of the compound.

开始日期2018-04-12

申办/合作机构

IRLAB Therapeutics AB

[+1]

NCT03531060

/ Completed临床1/2期

A Randomised, Double-blind, Placebo-controlled, Phase Ib Study Evaluating the Safety and Tolerability of IRL790 in Patients With Parkinson's Disease (PD) Experiencing Levodopa (L-Dopa) Induced Dyskinesia (LID).

This is a Phase 1b study investigating the safety and tolerability of IRl790 as adjunct therapy in patients with Parkinson disease. IRL790/placebo is taken for 28 days.

开始日期2016-11-08

申办/合作机构

IRLAB Therapeutics AB

100 项与 Mesdopetam 相关的临床结果

登录后查看更多信息

100 项与 Mesdopetam 相关的转化医学

登录后查看更多信息

100 项与 Mesdopetam 相关的专利（医药）

登录后查看更多信息

项与 Mesdopetam 相关的文献（医药）

2026-08-01·CLINICAL AUTONOMIC RESEARCH

Cardiovascular pharmacology of dopaminergic agents in humans: a review

Review

作者: Palma, Jose-Alberto ; Gomez Casanovas, Jose G

PURPOSE:

To review the cardiovascular effects of pharmacologic dopamine receptor modulation in humans, organized by receptor subtype.

METHODS:

Narrative review of human pharmacological, genetic, and clinical evidence linking dopamine receptor agonism and antagonism to blood pressure and heart rate changes in healthy volunteers and in patients with Parkinson disease, autonomic failure, psychiatric disorders, and selected cardiovascular conditions.

RESULTS:

Dopaminergic receptor agonism generally lowers blood pressure, with the magnitude of hypotension tracking with intrinsic activity: full orthosteric agonists (bromocriptine, ropirinole, apomorphine) carry the highest risk of orthostatic hypotension, and partial agonists (tavapadon) produce attenuated but clinically relevant hypotension. Dopamine D3-preferring agents (PF-592379, mesdopetam, cariprazine) have neutral cardiovascular effects in short-term trials. Levodopa-induced orthostatic hypotension arises from at least five converging mechanisms whose clinical impact is amplified by underlying neurogenic orthostatic hypotension. A notable exception is mevidalen, a centrally acting dopamine D1 positive allosteric modulator that paradoxically raises blood pressure. Despite murine knockout models consistently predicting that dopamine receptor deletion produces hypertension, pharmacological antagonism in humans does not reliably raise blood pressure: dopamine D1, D2, and D3 antagonists show largely neutral cardiovascular profiles, while antipsychotic-associated orthostatic hypotension is driven primarily by α1-adrenergic blockade.

CONCLUSIONS:

The cardiovascular response to dopaminergic agents depends on receptor selectivity, intrinsic activity, and baroreflex integrity. The discrepancy between murine-knockout-predicted hypertension and human pharmacological neutrality with antagonists, and the hypertensive effects of dopamine D1 positive allosteric modulators, represent key unresolved questions.

2026-04-01·CURRENT OPINION IN NEUROBIOLOGY

The challenges of experimental pharmacology in identifying novel treatments for Parkinson's disease

Review

作者: Huot, Philippe ; Teil, Margaux

An important part of the field of experimental pharmacology encompasses the study of the effects of molecules in animals. In the case of Parkinson's disease (PD), animal models have played an invaluable role in refining our understanding of the disease, in characterizing the effect of new compounds on the illness, and in bringing new treatments to the clinic. Indeed, it is now hardly conceivable that a drug would be tested in humans if several parameters pertaining to safety, toxicology, efficacy, etc. had not previously been evaluated in animal models. Quite unfortunately, efficacy in experimental models of PD does not necessarily guarantee positive clinical outcomes. In this article, which primarily focusses on the past five years, we review drugs that entered clinical trials for the treatment of levodopa-induced dyskinesia, parkinsonism, disease modification, and had previously been assessed in animal models of PD. The drugs discussed are buspirone, JM-010, befiradol, mesdopetam, foliglurax, dipraglurant, tavapadon, prasinezumab, cinpanemab, nilotinib, minzasolmin, exenatide, NLY01, liraglutide, lixisenatide, and semaglutide. For each molecule, we examine how previous preclinical studies succeeded or failed in predicting efficacy in clinical trials and discuss possible ways to optimize animal-model design and selection to maximize the probability of translational success.

2025-06-01·Movement Disorders Clinical Practice

Mesdopetam for the Treatment of Levodopa Induced Dyskinesia in Parkinson's Disease: A Randomized Phase 2b Trial

Article

作者: Angelo Antonini MD, PhD ; Joakim Tedroff MD, PhD ; Padraig O'Suilleabhain MD ; Susanna Waters MD, PhD ; Fabricio Stocchi MD, PhD ; Johanna Landström MSc ; Clas Sonesson PhD

Abstract:

Background:

The treatment of levodopa‐induced dyskinesia in Parkinson's disease (PD) is a largely unmet need.

Objectives:

Mesdopetam is a novel small molecule dopamine D3 receptor antagonist aimed for the treatment of levodopa‐induced dyskinesia. This was a phase 2b study dose finding study to investigate efficacy and safety of 2.5 mg, 5 mg and 7,5 mg b.i.d. in a randomized controlled trial.

Methods:

PD patients with ≥2 hours of troublesome dyskinesia were randomized to placebo or mesdopetam twice daily for 12 weeks. The primary efficacy endpoint was change from baseline to week 12 in ON time without troublesome dyskinesia (Good ON‐time) as recorded with home diaries. Secondary efficacy endpoints assessing ON phase dyskinesia were the modified UDysRS (sum of parts 1, 3 and 4) and MDS‐UPDRS part 4.2.

Results:

Groups did not differ in change from baseline to end of study in Good ON‐time. Several secondary assessments for ON phase dyskinesia such as the modified UDysRS showed clinically relevant and statistically significant improvements for the 2.5 and 7.5 mg doses. OFF time showed dose dependent decrease with highest efficacy for the 7.5 mg dose. The adverse event profile was similar to placebo.

Conclusions:

In this study mesdopetam failed to increase Good ON‐time as compared to placebo. However, a statistically significant and clinically meaningful improvement in the prespecified secondary efficacy endpoint UDysRS warrants further investigation. Results from this dose finding study suggest 7.5 mg b.i.d. to be the preferred dose for further study.

127

项与 Mesdopetam 相关的新闻（医药）

2026-10-20

·BioSpace

Nomination Committee Appointed for IRLAB’s Annual General Meeting 2027

GOTHENBURG, SE / ACCESS Newswire / October 20, 2026 / IRLAB Therapeutics AB (STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments for Parkinson's disease, today announces that the nomination committee ahead of the annual general meeting (AGM) 2027 has been appointed. According to the instruction for appointment of the nomination committee in IRLAB Therapeutics AB, resolved at the annual general meeting on May 22, 2024, the nomination committee shall, besides the Chair of the Board, consist of representatives of the three largest shareholders, or groups of shareholders, as of the last banking day in August 2026. The three largest shareholders or groups of shareholders have now appointed their representatives, thus the nomination committee ahead of the AGM 2027 has the following members: Daniel Johnsson , entrepreneur, business developer and investor. Appointed by a group of shareholders that consists of the company's founders representing about 11 per cent of shares and votes (Chairman) Joakim Tedroff , Chief Medical Officer (CMO) at IRLAB and one of IRLAB's founders. Appointed by a group of shareholders that consists of the company's founders representing about 8 per cent of shares and votes Patrik Mossberg , CEO and chairman of Marinvest representing about 3 per cent of shares and votes Janne Backman , Chair of the Board of IRLAB Therapeutics AB. Daniel Johnsson has been appointed Chairman of the nomination committee. The members of the nomination committee have been appointed by owners in IRLAB Therapeutics AB who represent a total of about 22 per cent of the total number of shares and votes in IRLAB Therapeutics AB as of the last banking day in August 2026. Information about the nomination committee's work and the instruction to the nomination committee can be found on the company website under the section for Corporate Governance. The nomination committee's proposal will be presented in the summon to the annual general meeting 2027 and on the company's web page, . The annual general meeting is planned to be held on June 3, 2027. Shareholders who wish to submit proposals to the nomination committee shall do this in writing, no later than January 31, 2027, via e-mail ir@irlab.se. For more information Kristina Torfgård, CEO Phone: +46 730 60 70 99 E-mail: kristina.torfgard@irlab.se For more information Gustaf Albèrt, CFO Phone: +46 709 168 302 E-mail: gustaf.albert@irlab.se About IRLAB IRLAB discovers and develops a portfolio of transformative treatments for all stages of Parkinson's disease. The company originates from Nobel Laureate Prof Arvid Carlsson's research group and the discovery of a link between brain neurotransmitter disorders and brain diseases. Mesdopetam (IRL790), under development for treating levodopa-induced dyskinesias, has completed Phase IIb and is in preparation for Phase III. Pirepemat (IRL752), currently in Phase IIb, is being evaluated for its effect on fall frequency in Parkinson's disease. IRL757, a compound being developed for the treatment of apathy in neurodegenerative disorders, is in Phase Ib. In addition, the company is developing two preclinical programs, IRL942 and IRL1117, towards Phase I studies. IRLAB's pipeline has been generated by the company's proprietary systems biology-based research platform Integrative Screening Process (ISP). Headquartered in Sweden, IRLAB is listed on Nasdaq Stockholm (IRLAB A). For more information, please visit . Attachments Nomination committee appointed for IRLAB’s annual general meeting 2027 SOURCE: IRLAB Therapeutics View the original press release on ACCESS Newswire

临床2期临床1期高管变更

2026-09-24

·BioSpace

IRLAB Appoints Janne Backman as New Chairman of the Board

GOTHENBURG, SWEDEN / ACCESS Newswire / September 24, 2026 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) - IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company discovering and developing novel treatments for Parkinson's disease, announces that Jan-Fredrik ("Janne") Backman today assumes the role of Chairman of the Board. He was elected Vice Chairman at the 2026 Annual General Meeting and now succeeds Carola Lemne, who announced back in the spring that she intended to step down from the position in September. Janne Backman has more than 20 years of experience in the life science industry. He has held positions including Senior Global Strategy and Marketing Director, Global Strategy and Marketing Director, and Global Program Director within R&D at The Medicines Company, where he led international commercialization strategies, EU product launches, and global development programs. In addition, he has held commercial roles at Merck Serono and AstraZeneca. Since 2016, he has served as CEO of J.F.B Consulting AB and J.F.B Invest. "It has been a privilege to lead IRLAB's Board of Directors during a period in which the company has built one of the most innovative and broadest pipelines in the Parkinson's disease field. After eight years of service on the Board, this feels like the right time to hand over the chairmanship. I am confident that Janne Backman, along with the rest of the Board, will contribute to maximizing the company's value creation for both patients worldwide and our shareholders," says Carola Lemne, outgoing Chairman of the Board of IRLAB Therapeutics. "On behalf of the entire Board, I would like to thank Carola Lemne for her contributions as Chairman of the Board. I look forward to leading the continued efforts to advance IRLAB's drug development programs and strengthen the company's ability to establish partnerships with international pharmaceutical companies," says Janne Backman, incoming Chairman of the Board of IRLAB Therapeutics. About IRLAB IRLAB discovers and develops a portfolio of transformative treatments for all stages of Parkinson's disease. The company originates from Nobel Laureate Prof Arvid Carlsson's research group and the discovery of a link between brain neurotransmitter disorders and brain diseases. Mesdopetam (IRL790), under development for treating levodopa-induced dyskinesias, has completed Phase IIb and is in preparation for Phase III. Pirepemat (IRL752), currently in Phase IIb, is being evaluated for its effect on fall frequency in Parkinson's disease. IRL757, a compound being developed for the treatment of apathy in neurodegenerative disorders, is in Phase Ib. In addition, the company is developing two preclinical programs, IRL942 and IRL1117, towards Phase I studies. IRLAB's pipeline has been generated by the company's proprietary systems biology-based research platform Integrative Screening Process (ISP). Headquartered in Sweden, IRLAB is listed on Nasdaq Stockholm (IRLAB A). For more information, please visit . For more information Jan-Fredrik Backman, Chairman Tel: +46 702 35 65 00 E-post: janne.backman@irlab.se Kristina Torfgård, CEO Tel: +46 730 60 70 99 E-post: kristina.torfgard@irlab.se Attachments IRLAB Appoints Janne Backman as New Chairman of the Board SOURCE: IRLAB Therapeutics View the original press release on ACCESS Newswire

临床2期高管变更临床1期

2026-09-03

·BioSpace

IRLAB’s CEO Intends to Step Down During the First Quarter of 2027

GOTHENBURG, SE / ACCESS Newswire / September 3, 2026 / IRLAB Therapeutics AB (STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments for Parkinson's disease, announces today that Kristina Torfgård has informed the Board of Directors that she wishes to step down from her position as CEO. She will remain in the CEO role until the first quarter of 2027, creating good conditions for a smooth transition to her successor. The Board of Directors will immediately initiate the work to ensure a well-structured leadership transition. "On behalf of the Board of Directors, I would like already now to extend a warm thank you to Kristina Torfgård for her contributions as CEO. We appreciate that she has notified the Board of her intention with such good advance notice and are convinced that she will continue her solid and committed work so that IRLAB can bring the ongoing partner discussions all the way to completion. At the same time, progress continues in the ongoing clinical study of the drug candidate linepemat, and the company's financial runway extends beyond the planned readout of results in mid-2027. We are now immediately initiating the process of finding a suitable successor for the CEO position," says Carola Lemne, Chair of the Board of IRLAB Therapeutics. "It is with mixed feelings that I have informed the Board that I wish to leave IRLAB, a company that I am proud to have been part of. With a successful capital raise behind us and intensive ongoing activities to secure the next revenue-generating collaboration agreement, I now look forward to continuing to work to deliver on our stated goals until I take the next step in my professional life at the beginning of next year," says Kristina Torfgård, CEO of IRLAB Therapeutics. For more information: ezstandalone.cmd.push(function () { ezstandalone.showAds(131); }); Carola Lemne, Chair of the Board Phone: +46 722 25 28 20 E-mail: carola.lemne@irlab.se This information is information that IRLAB Therapeutics is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-09-03 10:55 CEST. About IRLAB IRLAB discovers and develops a portfolio of transformative treatments for all stages of Parkinson's disease. The company originates from Nobel Laureate Prof Arvid Carlsson's research group and the discovery of a link between brain neurotransmitter disorders and brain diseases. Mesdopetam (IRL790), under development for treating levodopa-induced dyskinesias, has completed Phase IIb and is in preparation for Phase III. Pirepemat (IRL752), currently in Phase IIb, is being evaluated for its effect on fall frequency in Parkinson's disease. IRL757, a compound being developed for the treatment of apathy in neurodegenerative disorders, is in Phase Ib. In addition, the company is developing two preclinical programs, IRL942 and IRL1117, towards Phase I studies. IRLAB's pipeline has been generated by the company's proprietary systems biology-based research platform Integrative Screening Process (ISP). Headquartered in Sweden, IRLAB is listed on Nasdaq Stockholm (IRLAB A). For more information, please visit . ezstandalone.cmd.push(function () { ezstandalone.showAds(132); }); Attachments IRLAB’s CEO intends to step down during the first quarter of 2027 SOURCE: IRLAB Therapeutics View the original press release on ACCESS Newswire

临床2期临床1期高管变更

100 项与 Mesdopetam 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
药物性运动障碍	临床2期	美国	IRLAB Therapeutics AB	2020-10-29
药物性运动障碍	临床2期	法国	IRLAB Therapeutics AB	2020-10-29
药物性运动障碍	临床2期	以色列	IRLAB Therapeutics AB	2020-10-29
药物性运动障碍	临床2期	意大利	IRLAB Therapeutics AB	2020-10-29
药物性运动障碍	临床2期	波兰	IRLAB Therapeutics AB	2020-10-29
药物性运动障碍	临床2期	塞尔维亚	IRLAB Therapeutics AB	2020-10-29
帕金森病	临床2期	瑞典	IRLAB Therapeutics AB	2018-04-12
帕金森病	临床2期	英国	IRLAB Therapeutics AB	2018-04-12
运动失调	临床2期	-	IRLAB Therapeutics AB	2016-11-08

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04435431 (CTgov)	临床2期	药物性运动障碍 \| 帕金森病	155	Placebo	積繭選築壓積鏇淵顧鬱(膚蓋窪糧觸蓋築觸範選) = 鏇簾鑰範觸獵鏇壓蓋鬱網餘鹹顧壓獵齋構鑰夢 (網選餘蓋餘餘鏇觸鹽廠, 0.4776) 更多	-	2024-03-06
NCT04435431 \| EUCTR2020-002010-41-FR (Biospace) 人工标引	临床2期	帕金森病	156	mesdopetam	顧糧繭築衊築衊夢蓋襯(觸夢膚鑰遞膚鏇顧鹹醖) = 襯壓遞築鹹廠齋遞網壓選襯鏇範顧鏇構蓋糧觸 (觸窪鏇窪壓鬱顧製觸顧 ) 更多	积极	2023-08-21
NCT04435431 \| EUCTR2020-002010-41-FR (Biospace) 人工标引	临床2期	帕金森病	156	placebo	獵餘選獵鑰網淵餘壓繭(衊壓膚夢網積遞鏇網繭) = 鏇積鹹顧壓網廠積選願築鑰簾艱艱簾鹽鬱願選 (膚獵簾遞願鹹鹹齋顧願 ) 更多	积极	2023-08-21
NCT03368170 (CTgov)	临床2期	帕金森病	75	Mesdopetam	餘餘選憲顧顧鹽鑰襯構(淵夢襯獵積膚窪鹹簾範) = 膚願構顧窪蓋壓網範構選遞築鬱窪鏇製醖壓膚 (憲遞糧襯網膚鹽積積築, 齋願顧壓簾構廠醖鹹築 ~ 構顧襯構夢觸鏇簾獵鬱) 更多	-	2020-03-24
NCT03531060 (Pubmed \| NPJ Parkinsons Dis) 人工标引	临床1期	运动失调 \| 帕金森病	15	IRL790	憲鏇糧廠鹽範襯蓋遞壓(餘鹽齋構淵獵鏇醖憲夢) = 鹹願獵製淵鬱選蓋願積醖觸遞選蓋構簾淵蓋醖 (齋觸糧鑰選糧構鏇壓壓 ) 更多	积极	2018-12-06
NCT03531060 (Pubmed \| NPJ Parkinsons Dis) 人工标引	临床1期	运动失调 \| 帕金森病	15	Placebo	憲鏇糧廠鹽範襯蓋遞壓(餘鹽齋構淵獵鏇醖憲夢) = 壓廠鏇鏇鏇淵繭觸憲淵醖觸遞選蓋構簾淵蓋醖 (齋觸糧鑰選糧構鏇壓壓 ) 更多	积极	2018-12-06
MDS2018	临床1期	药物性运动障碍 \| 帕金森病 dopamine D3 receptor	-	IRL790	遞鬱膚憲餘繭蓋繭鏇醖(構醖觸憲遞網鹽蓋願窪) = Adverse events were mostly reported during the titration phase of the trial. They were mainly central nervous system related and could be mitigated by dose adjustments. There were no serious adverse events. 艱鑰積願蓋簾繭膚繭鹽 (製艱鏇製遞範鹹餘鹽蓋 ) 更多	积极	2018-10-05